A Study on Advanced Gastric Cancer Cure by Medical Oncologists in China Wins American Award
Published By : 09 Jun 2014 | Published By : QYRESEARCH
Chinese doctors who won for their new study on the treatment of advanced gastric cancer presented a program based on the same at the American Society of Clinical Oncology (ASCO) in Illinois.
The American Society of Clinical Oncology decided to have the study as this year’s best recipient of the Excellent Paper award, as well as the honor of being named as the 2014 Best of ASCO. Around 32 medical centers across China participated in this study which was focused on the development and expansion of Apatinib mesylate tablets for the treatment of advanced gastric cancer. The American Society of Clinical Oncology chose to reward the medical oncologists in China who were leading the study for their great work and efforts in developing innovative treatments in curing cancer therapy in the country.
The study was led by Shukui Qin, former chairman of the Chinese Society of Clinical Oncology, and also by Professor Jin Li, the present vice-chairman of CSCO.
Gastric cancer is rated as the third leading chronic disease causing cancer-related deaths in China. It has afflicted around 352,300 Chinese people each year, and approximately around 952,000 new gastric cancer cases are diagnosed worldwide with 47 percent of those present in China.
The study also claims that around 60 to 80 percent of the people affected with this disease are diagnosed when their cancer stage reaches the last stage, leaving them with very limited treatment options. Only 20 percent of those who are diagnosed with gastric cancer fight or survive the disease for five years or more.
In the recent years, there were many studies and researches conducted for developing new drugs for advanced gastric cancer treatment; however, very few had success.
The Apatinib mesylate tablets developed from drug developer Jiangsu Hengrui Medicine Co, Ltd. are now under scrutiny review for basic registration and approval for marketing in China.
Every year, there are thousands of participants attending the annual ASCO meeting of the medical oncology field. This year’s convention program was held in Chicago from May 30 until June 3.
ASCO being the most authoritative and influential academic group in the field of clinical oncology, hold yearly meetings and exhibits the most recent developments in treating cancer.